Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2023-03-31, filed 2023-05-15, with 11 holding rows worth $143,374,414.

Accession
0001814554-23-000002
Filed
2023-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2023

A holdings report, 11 entries on the cover page, a total value of $143,374,414 stated on the cover page (in dollars after the unit check, H1), rows summing to $143,374,414 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIQUIDIA CORPORATION COM NEW53635D202Stock9,243,627$63,873,463dollars as filed
ANIKA THERAPEUTICS INC035255108COM715,291$20,543,158dollars as filed
STANDARD BIOTOOLS INC34385P108COM8,576,799$16,724,758dollars as filed
EXELIXIS INC COM30161Q104Stock850,000$16,498,500dollars as filed
EVOLUS INC30052C107COM1,523,484$12,888,675dollars as filed
ADMA BIOLOGICS INC000899104COM1,662,613$5,503,249dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS183,064$3,675,925dollars as filed
SOCIETAL CDMO INC75629F109COM1,077,268$1,281,949dollars as filed
EYEPOINT INC COM NEW30233G209Stock435,298$1,279,776dollars as filed
ALIMERA SCIENCES INC016259202COM478,777$1,005,432dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM4,333$99,529dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001814554-23-000002this filing2023-05-15acceptance time not in the bulk data set